Category: biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma fold, using up the leading science area at Sanofi.Quigley

.Sanofi has actually made a late entry to the radioligand event, paying one hundred thousand euros ($ 110 thousand) upfront for international rights to a

.Sanofi has actually quit a phase 2 ordeal of Denali Therapeutics-partnered oditrasertib in numerous sclerosis. The French drugmaker tore the RIPK1 inhibitor difficulty coming from

.Sangamo Rehabs has actually determined a faster way to market for its own Fabry disease applicant, lining up along with the FDA on a process

.Sage Therapeutics’ newest effort to diminish its own pipeline and also staff will certainly find a third of the biotech’s employees going to the exits

.Matt Gline is actually back along with a brand new ‘vant’ provider, after the Roivant Sciences CEO spent Bayer $14 million ahead of time for

.Roche has actually come back the rights to UCB’s anti-tau antitoxin bepranemab, ignoring a $120 thousand bet on the Alzheimer’s ailment medication prospect on the

.Roche is actually storing out hopes that its own injectable weight problems prospect could at some point demonstrate 25% weight-loss in late-stage trials, the pharma’s

.Roche’s chronic cough program has sputtered to a stop. The drugmaker, which axed the plan after the drug applicant let down in period 2, divulged

.After creating a gene therapy relationship with Dyno Therapies in 2020, Roche is back for additional.In a new package likely worth much more than $1